StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)

Close on Nov 17, 2026Market cap $792.02MP/E –Yield –

Lexicon Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Lexicon Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $60.27M, down 27.8% year over year. For fiscal 2025 it was $61.12M, down 27.7% from the year before. Over ten years it grew -4.3% a year on average. The highest annual figure on record is $163.97M in fiscal 2016.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$61.12M-27.7%
FY2024Dec 31, 2024$84.48M+43.5%
FY2023Dec 31, 2023$58.89M+11.5%
FY2022Dec 31, 2022$52.82M-4.1%
FY2021Dec 31, 2021$55.05M-64.2%
FY2020Dec 31, 2020$153.62M+67.1%
FY2019Dec 31, 2019$91.92M-8.3%
FY2018Dec 31, 2018$100.24M-34.1%
FY2017Dec 31, 2017$152.22M-7.2%
FY2016Dec 31, 2016$163.97M+72.3%
FY2015Dec 31, 2015$95.19M+6.6%
FY2014Dec 31, 2014$89.28M-0.4%
FY2013Dec 31, 2013$89.68M+8.6%
FY2012Dec 31, 2012$82.57M-10.1%
FY2011Dec 31, 2011$91.83M+16.9%
FY2010Dec 31, 2010$78.52M-3.3%
FY2009Dec 31, 2009$81.24M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.44M+10.8%
Q1 FY2026Mar 31, 2026$12.76M-16.6%
Q4 FY2025Dec 31, 2025$11.32M-57.6%
Q3 FY2025Sep 30, 2025$18.76M-27.2%
Q2 FY2025Jun 30, 2025$15.75M-10.7%
Q1 FY2025Mar 31, 2025$15.30M+6.5%
Q4 FY2024Dec 31, 2024$26.69M+80.8%
Q3 FY2024Sep 30, 2024$25.78M+46.8%
Q2 FY2024Jun 30, 2024$17.64M+21.3%
Q1 FY2024Mar 31, 2024$14.37M+19.5%
Q4 FY2023Dec 31, 2023$14.76M+5.6%
Q3 FY2023Sep 30, 2023$17.56M+66.3%
Q2 FY2023Jun 30, 2023$14.54M+8.9%
Q1 FY2023Mar 31, 2023$12.03M-19.4%
Q4 FY2022Dec 31, 2022$13.98M-15.3%
Q3 FY2022Sep 30, 2022$10.56M-32.7%
Q2 FY2022Jun 30, 2022$13.36M+30.2%
Q1 FY2022Mar 31, 2022$14.93M+18.4%
Q4 FY2021Dec 31, 2021$16.50M+1563.1%
Q3 FY2021Sep 30, 2021$15.68M-60.9%
Q2 FY2021Jun 30, 2021$10.26M-82.1%
Q1 FY2021Mar 31, 2021$12.61M-77.1%
Q4 FY2020Dec 31, 2020$992.00K-97.6%
Q3 FY2020Sep 30, 2020$40.15M+50.6%
Q2 FY2020Jun 30, 2020$57.30M+353.4%
Q1 FY2020Mar 31, 2020$55.18M+359.0%
Q4 FY2019Dec 31, 2019$40.61M+229.9%
Q3 FY2019Sep 30, 2019$26.66M+93.7%
Q2 FY2019Jun 30, 2019$12.64M-52.3%
Q1 FY2019Mar 31, 2019$12.02M-74.8%
Q4 FY2018Dec 31, 2018$12.31M-71.1%
Q3 FY2018Sep 30, 2018$13.76M-64.8%
Q2 FY2018Jun 30, 2018$26.48M-1.7%
Q1 FY2018Mar 31, 2018$47.70M+9.4%
Q4 FY2017Dec 31, 2017$42.57M+62.3%
Q3 FY2017Sep 30, 2017$39.14M-25.5%
Q2 FY2017Jun 30, 2017$26.93M–
Q1 FY2017Mar 31, 2017$43.58M–
Q4 FY2016Dec 31, 2016$26.22M–
Q3 FY2016Sep 30, 2016$52.53M–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?